Clinical Trials
618 trialsBuMelMCRN001
University Health Network, Toronto
REVALLO
University Hospital, Bordeaux
Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)
M.D. Anderson Cancer Center
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
M.D. Anderson Cancer Center
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
M.D. Anderson Cancer Center
CONQUISTADOR
Universitätsklinikum Hamburg-Eppendorf
Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma
Medical College of Wisconsin
PrE1005
PrECOG, LLC.
SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
Roswell Park Cancer Institute
Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone
Universitätsklinikum Hamburg-Eppendorf
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
M.D. Anderson Cancer Center
CUREMZL002
Institute of Hematology & Blood Diseases Hospital, China
MASTER-2
University of Alabama at Birmingham
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
Mayo Clinic
ZGR
Institute of Hematology & Blood Diseases Hospital, China
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
ZGR in TN FL
Institute of Hematology & Blood Diseases Hospital, China
Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma
Mayo Clinic
A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation
Memorial Sloan Kettering Cancer Center
Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
M.D. Anderson Cancer Center
REFRACT
University of Birmingham
Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma
City of Hope Medical Center
Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation
UNC Lineberger Comprehensive Cancer Center
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
The First Affiliated Hospital of Soochow University
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
Dana-Farber Cancer Institute
Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
Weill Medical College of Cornell University
FASTER
SCRI Development Innovations, LLC
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
City of Hope Medical Center
Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
University of Chicago
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
Wake Forest University Health Sciences
Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
M.D. Anderson Cancer Center
FORTE
University of Turin, Italy
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
University of Chicago
Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study
Weill Medical College of Cornell University
RICER
Hackensack Meridian Health
IFM2017_03
University Hospital, Lille
ECLAT
Memorial Sloan Kettering Cancer Center
IFM2005-02
University Hospital, Toulouse
IFM/DFCI2009
University Hospital, Toulouse
FCR
Hackensack Meridian Health
Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant
Roswell Park Cancer Institute
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
Hackensack Meridian Health
ADVANCE
University of Miami
MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
Ruijin Hospital
QUAD
Hackensack Meridian Health
Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells
New Approaches to Neuroblastoma Therapy Consortium
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing
Vanderbilt-Ingram Cancer Center
IFm2022-01
Nantes University Hospital